Subtopic Deep Dive

Thyroid Disease in Pregnancy
Research Guide

What is Thyroid Disease in Pregnancy?

Thyroid Disease in Pregnancy encompasses thyroid dysfunction during gestation and postpartum, focusing on maternal thyroid hormone impacts on fetal development and clinical management guidelines.

Key ATA guidelines from Stagnaro-Green et al. (2011, 2923 citations) and Alexander et al. (2017, 2592 citations) provide evidence-based recommendations for diagnosis and levothyroxine dosing. Endocrine Society guidelines by De Groot et al. (2012, 1848 citations) update management strategies. Over 10,000 citations across major papers highlight prevalence data from NHANES III by Hollowell (2002, 1021 citations).

15
Curated Papers
3
Key Challenges

Why It Matters

Maternal hypothyroidism links to fetal IQ deficits, as shown in Lazarus et al. (2012, 626 citations) where antenatal screening failed to improve child cognition at age 3. Optimized levothyroxine dosing per ATA guidelines (Alexander et al., 2017) prevents neurocognitive impairments in 5-10% of pregnancies with subclinical hypothyroidism. Postpartum monitoring reduces relapse risks in Graves' disease, impacting maternal health and breastfeeding (Stagnaro-Green et al., 2011). These interventions affect millions annually, given 2-3% U.S. prevalence of thyroid antibodies (Hollowell, 2002).

Key Research Challenges

Optimal Levothyroxine Dosing

Pregnancy increases levothyroxine needs by 30-50%, requiring trimester-specific TSH targets (Alexander et al., 2017). RCTs show variable fetal outcomes from dosing errors (Lazarus et al., 2012). Balancing maternal euthyroidism against overdose risks persists.

Screening Effectiveness

Universal TSH screening debates continue after negative Controlled Antenatal Thyroid Screening Study results (Lazarus et al., 2012, 626 citations). ATA recommends targeted screening for high-risk groups (Stagnaro-Green et al., 2011). Cost-effectiveness in low-prevalence settings remains unresolved.

Postpartum Thyroiditis Management

10-20% of women develop transient hyper/hypothyroidism postpartum, per Endocrine Society guidelines (De Groot et al., 2012). Long-term hypothyroidism risk stratification lacks prospective data. Monitoring protocols vary across guidelines.

Essential Papers

1.

Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum

Alex Stagnaro‐Green, Marcos Abalovich, Erik K. Alexander et al. · 2011 · Thyroid · 2.9K citations

We have developed evidence-based recommendations to inform clinical decision-making in the management of thyroid disease in pregnant and postpartum women. While all care must be individualized, suc...

2.

2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis

Douglas S. Ross, Henry B. Burch, David S. Cooper et al. · 2016 · Thyroid · 2.7K citations

One hundred twenty-four evidence-based recommendations were developed to aid in the care of patients with thyrotoxicosis and to share what the task force believes is current, rational, and optimal ...

3.

2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum

Erik K. Alexander, Elizabeth N. Pearce, Gregory A. Brent et al. · 2017 · Thyroid · 2.6K citations

Background: Thyroid disease in pregnancy is a common clinical problem. Since the guidelines for the management of these disorders by the American Thyroid Association (ATA) were first published in 2...

4.

Management of Thyroid Dysfunction during Pregnancy and Postpartum: An Endocrine Society Clinical Practice Guideline

Leslie De Groot, Marcos Abalovich, Erik K. Alexander et al. · 2012 · The Journal of Clinical Endocrinology & Metabolism · 1.8K citations

Abstract Objective: The aim was to update the guidelines for the management of thyroid dysfunction during pregnancy and postpartum published previously in 2007. A summary of changes between the 200...

5.

Serum TSH, T4, and Thyroid Antibodies in the United States Population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III)

Jennifer Hollowell · 2002 · The Journal of Clinical Endocrinology & Metabolism · 1.0K citations

NHANES III measured serum TSH, total serum T4, antithyroperoxidase (TPOAb), and antithyroglobulin (TgAb) antibodies from a sample of 17,353 people aged ≥12 yr representing the geographic and ethnic...

6.

Growth Hormone, Insulin-Like Growth Factors, and the Skeleton

Andrea Giustina, Gherardo Mazziotti, Ernesto Canalis · 2008 · Endocrine Reviews · 883 citations

GH and IGF-I are important regulators of bone homeostasis and are central to the achievement of normal longitudinal bone growth and bone mass. Although GH may act directly on skeletal cells, most o...

7.

The Incidence and Prevalence of Thyroid Dysfunction in Europe: A Meta-Analysis

Ane Garmendia Madariaga, Silvia Santos Palacios, Francisco Guillén‐Grima et al. · 2014 · The Journal of Clinical Endocrinology & Metabolism · 761 citations

This meta-analysis provides extensive data on the prevalence and incidence of thyroid dysfunction in Europe.

Reading Guide

Foundational Papers

Start with Stagnaro-Green et al. (2011, 2923 citations) for core ATA recommendations on diagnosis/dosing; De Groot et al. (2012, 1848 citations) for Endocrine Society comparisons; Hollowell (2002) for U.S. prevalence baselines.

Recent Advances

Alexander et al. (2017, 2592 citations) updates ATA with new evidence; Ross et al. (2016, 2688 citations) covers thyrotoxicosis specifics; Léger et al. (2014) for congenital hypothyroidism links.

Core Methods

TSH/free T4 serial monitoring; levothyroxine dose titration to TSH 0.1-2.5 mU/L; TPOAb testing for risk stratification; cohort studies/RCTs assess neurodevelopmental outcomes.

How PapersFlow Helps You Research Thyroid Disease in Pregnancy

Discover & Search

Research Agent uses searchPapers with 'thyroid disease pregnancy guidelines' to retrieve Stagnaro-Green et al. (2011, 2923 citations); citationGraph maps evolution from 2011 ATA to Alexander et al. (2017); findSimilarPapers expands to De Groot et al. (2012); exaSearch uncovers cohort studies on fetal IQ.

Analyze & Verify

Analysis Agent applies readPaperContent to extract TSH targets from Alexander et al. (2017), then verifyResponse with CoVe against Lazarus et al. (2012) for screening claims; runPythonAnalysis meta-analyzes prevalence from Hollowell (2002) and Madariaga (2014) using pandas; GRADE grading scores guideline evidence as high for levothyroxine RCTs.

Synthesize & Write

Synthesis Agent detects gaps in postpartum monitoring between Stagnaro-Green (2011) and Alexander (2017), flags contradictions on universal screening; Writing Agent uses latexEditText for guideline comparisons, latexSyncCitations for 10+ papers, latexCompile for report PDF, exportMermaid for TSH trajectory diagrams.

Use Cases

"Extract prevalence of hypothyroidism in pregnant women from NHANES data"

Research Agent → searchPapers(NHANES thyroid) → Analysis Agent → readPaperContent(Hollowell 2002) → runPythonAnalysis(pandas extraction of TSH/TPOAb rates by age) → CSV table with 4.4% prevalence in women 12+.

"Compare ATA 2011 vs 2017 levothyroxine dosing guidelines"

Research Agent → citationGraph(ATA guidelines) → Synthesis Agent → gap detection → Writing Agent → latexEditText(table), latexSyncCitations(Stagnaro-Green 2011, Alexander 2017), latexCompile → PDF with trimester dose increases.

"Find analysis code for thyroid antibody trends in pregnancy cohorts"

Research Agent → paperExtractUrls(Lazarus 2012) → paperFindGithubRepo(thyroid pregnancy stats) → githubRepoInspect(R scripts) → runPythonAnalysis(adapt to Hollowell 2002 data) → matplotlib plots of antibody prevalence.

Automated Workflows

Deep Research workflow conducts systematic review: searchPapers(50+ thyroid pregnancy) → citationGraph → GRADE all → structured report on management evolution from De Groot (2012) to Alexander (2017). DeepScan applies 7-step analysis with CoVe checkpoints to verify Lazarus (2012) screening claims against NHANES baselines. Theorizer generates hypotheses on optimal TSH cutoffs from guideline contradictions.

Frequently Asked Questions

What defines thyroid disease in pregnancy?

Hypothyroidism or hyperthyroidism during gestation/postpartum, with TSH >2.5 mU/L or <0.1 mU/L prompting evaluation per ATA guidelines (Alexander et al., 2017).

What are main management methods?

Levothyroxine for hypothyroidism (increase 30-50% early pregnancy); propylthiouracil for hyperthyroidism first trimester (Stagnaro-Green et al., 2011; Ross et al., 2016).

What are key papers?

Stagnaro-Green et al. (2011, 2923 citations) ATA guidelines; Alexander et al. (2017, 2592 citations) update; Lazarus et al. (2012, 626 citations) on screening futility.

What open problems exist?

Universal screening benefits unproven (Lazarus 2012); personalized dosing models needed beyond weight-based; long-term offspring outcomes from subclinical cases lack RCTs.

Research Thyroid Disorders and Treatments with AI

PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:

Start Researching Thyroid Disease in Pregnancy with AI

Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.